XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2023
Sep. 30, 2023
Current Assets:    
Cash and cash equivalents $ 20,345,618 $ 26,480,928
Prepaid expenses 7,864,496 7,889,506
Total Current Assets 28,210,114 34,370,434
Property and equipment, net 854 1,432
Operating lease right-of-use asset, net 403,996 454,426
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 97,399,822 103,611,150
Current Liabilities:    
Accounts payable 2,647,251 2,927,334
Accrued expenses 276,897 476,300
Accrued compensation 2,430,671 2,156,983
Operating lease liability 224,000 218,380
Total Current Liabilities 5,578,819 5,778,997
Deferred tax liability 6,281,800 6,137,800
Operating lease liability – noncurrent 204,569 262,865
Total Liabilities 12,065,188 12,179,662
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 158,966,576 and 158,857,798 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively 158,967 158,858
Additional paid-in capital 256,037,851 252,903,629
Accumulated deficit (171,462,564) (162,231,379)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 84,734,254 90,831,108
Non-controlling interest 600,380 600,380
Total Equity 85,334,634 91,431,488
Total Liabilities and Equity $ 97,399,822 $ 103,611,150